Current intensive treatment for AML includes cytotoxic chemotherapy, and autologous or allogeneic stem cell transplantation, and since the approval of new targeted therapies such as FLT3 inhibitors, IDH inhibitors, BCL2 inhibitors or anti-CD33 antibody drug conjugate, personalized treatment strategies have become possible for a subgroup of patients (Döhner et al., 2022). This evidence concerns the gene FLT3 and acute myeloid leukemia.